# Biomarker - Panitumumab Response With KRAS Wild Type MCC

> **NCT00853931** · NA · COMPLETED · sponsor: **British Columbia Cancer Agency** · enrollment: 52 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Panitumumab

## Key facts

- **NCT ID:** NCT00853931
- **Lead sponsor:** British Columbia Cancer Agency
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2015-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00853931

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00853931, "Biomarker - Panitumumab Response With KRAS Wild Type MCC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00853931. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*